Contineum, J&J's depression drug fails to meet mid-stage trial goal

Contineum Therapeutics said on Monday an experimental depression drug it developed with Johnson & ​Johnson failed to meet the main goal ‌of a mid-stage study.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。